Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)

closed

This NOFO invites applications that apply existing or newly developed artificial intelligence and machine learning methods (AI/ML) to various aspects of drug discovery and preclinical drug development to accelerate the identification, optimization, and selection of preclinical drug candidates for the treatment and prevention of Alzheimers disease (AD) and AD-related dementias ADRD and increase their likelihood of success during clinical drug development.This program will also create advanced open-source analytical tools that will be made available to researchers in academia and biotech/pharma for more effective prosecution of AD/ADRD drug discovery campaigns for novel targets.